NASH (Non-alcoholic Steatohepatitis) Biomarkers market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the NASH (Non-alcoholic Steatohepatitis) Biomarkers market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others
Segment by Application
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
GENFIT SA
Gilead Sciences, Inc. (GILD)
AstraZeneca
Novartis AG
Bristol-Myers Squibb Company
Allergan Plc
Novo Nordisk A/S
Boehringer Ingelheim
Pfizer Inc
